Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
An all-female panel of amfAR-funded HIV scientists share insights on sex differences in the HIV reservoir, gender in research and more.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Samuel Weissman won second place at the 2019 Regeneron Science Talent Search. Next, he wants to help cure HIV.
In a study of people with a low but detectable viral load despite adherence to treatment, infected cells were apparently cloning themselves.
Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.
HIV cure research has principally focused on latently infected CD4 cells as the backbone of the viral reservoir.
Experimental agent shrinks HIV reservoir, but fails to delay viral rebound.
The inability to precisely assess reservoir size has greatly hindered efforts to determine the effects of experimental cure therapies.
Researchers examined differences in the strength of a gene called nef.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
Beginning six months of treatment within two days following infection prevented viral rebound in at least some animals in a recent study.
Researchers believe that macrophage cells in the liver that harbor such inert HIV are not a part of the viral reservoir.
As a result, cure treatments may have to approach these two targets differently.
Such latently infected cells remain under the radar of antiretroviral treatment, which only works on replicating cells.
A recent study found that agents used to wake up resting HIV-infected cells probably work only on 5 percent of such cells.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.